Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 2, 2025

Partial Published before the outcome was known, scored automatically when the window closed on September 30, 2025 — -19.5% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$67.47 – $68.45Entry zone — fair-value band

$68.97Published — price the day we called it

$86.61Target — the price the thesis aimed for

$71.00Peak — highest point inside the window, not a realized return

$55.49Window close — end-of-window price, context only

What happened

Partial

Reached 11% of the predicted growth at its peak, without hitting the target.

At window close

-19.5%

realized, from the publication price to the last close inside the window

Peak gain

+2.9%

peak, from the publication price — not a realized return

S&P 500, same window

+7.7%

SPY over the identical days, dividend-adjusted

Window close

$55.49

last close inside the window, ended September 30, 2025

Peak price

$71.00

peak on July 25, 2025 — not a realized return

Days to target

—

The thesis — published July 2, 2025

Predicted growth

+27%

over the measurement window

Target price

$86.61

the price the thesis aimed for

Entry zone

$67.47 – $68.45

the fair-value band we waited for

Price at publication

$68.97

published July 2, 2025

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is the clear leader in modern diabetes and weight-loss medicines. A new July 2 study says sales of its key drug family could more than double to $62 billion by 2033. The share price recently slid after the company ended a disputed promotion deal, a step that keeps its brand trusted. Because profits are strong, investors expect the stock to move toward about $89 over the next quarter as demand keeps growing.

Primary drivers

July study predicts the market for these medicines could double by 2033.
Cutting ties with Hims keeps the brand strong and lowers lawsuit worries.
Price dipped and is near its recent average price, giving a potential entry.
Big profit margins and solid fundamentals hint the share price can rebound.

How it played out

NVO: target was not reached

Lyra published NVO at 68.97 on 2025-07-02 with expected growth of 27%. The thesis pointed to leadership in diabetes and weight-loss medicines, a July study that said the key drug family could more than double to $62 billion by 2033, the end of a disputed promotion deal, strong profits, and a possible move toward 86.61.

Inside the window, NVO peaked at 71 on 2025-07-25, a 2.9% gain. It stayed below the 86.61 target and never reached it. By 2025-09-30, it ended at 55.49. The thesis missed.

What happened during the window

On 2025-07-29, Novo Nordisk named Maziar Mike Doustdar as president and chief executive officer and lowered its 2025 outlook. On 2025-09-10, the company announced a restructuring with 9,000 roles affected and another change to its 2025 operating profit outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals